Attorneys in our Health Care & Life Sciences Group counsel health care providers, insurers, biopharmaceutical and device companies, and other entities throughout the country with respect to their most sophisticated legal challenges.

We strive to provide outstanding value to our clients while maintaining the highest professional standards in our work. Our success in doing so is evidenced by our selection as counsel by some of the largest, most highly regarded health care organizations in the country, as well as by smaller clients striving to make or expand their place in the health care market.

Our attorneys are consistently recognized by Chambers USA: America's Leading Lawyers for Business and The Best Lawyers in America for their dedication, superior skills, and practical savvy. We are a sought-after partner to health care businesses of all types and welcome the unique challenges and relationships each partnership brings.

We serve clients operating across the health care industry, including:

  • Academic medical centers
  • Hospitals and health care systems
  • Health centers (including FQHCs)
  • Multi-provider networks (ACOs, CINs, IDSs, IPAs, PHOs)
  • Universities and schools of medicine
  • Health plans and managed care companies
  • Pharmaceutical, biotechnology, and medical device companies
  • Physician groups
  • Health care data analysis companies
  • Commercial IRBs
  • Professional associations and societies
  • Ambulatory surgery centers
  • Health information technology companies
  • Research institutes
  • Laboratories (clinical, research, and others)
  • Government agencies
  • Research funders
  • Contract research organizations and other research service providers
  • Organ procurement organizations

We also provide a full range of strategic, regulatory, and government enforcement and litigation legal services. For more information on these services, please see the service line pages listed below.

Firm Highlights

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...